Sector: Life Sciences

Latest content

The EU’s UPC launch is imminent – here’s what IP strategists need to know

Companies must now make tough decisions about which rights to opt out of the new unified European patent system

25 January 2022

Moderna, Nike and TSMC among pandemic-era outperformers in patent portfolio strength

Innovation metric that’s agnostic to patent quantity highlights diverse group of companies that have put distance between themselves and their competition over the past two years

25 January 2022

AstraZeneca continues its winning out-licensing/in-licensing strategy

The Anglo-Swedish company has been a trailblazer in the monetisation of deprioritised IP

21 January 2022

Discretionary denials impact US life sciences IP strategies, but not as much as might be thought

SCOTUS refuses to consider NHK-Fintiv legal challenges, with significant implications for PTAB actions

20 January 2022

WHO’s vaccine successes show significance of Moderna covid IP pledge

African tech transfer hub is making fast progress in replicating the approved mRNA jab

18 January 2022

Skinny label concerns persist for generics, despite good news from Delaware

A district court judge has thrown out an induced infringement allegation against Hikma Pharmaceutical, but big questions remain over drug label carve-outs

14 January 2022

mRNA vaccines: how to navigate the freedom-to-operate maze

The Long Read: Jeffrey Morton and Thomas Ehrich unpack the complex patent considerations surrounding one of the most important leaps forward in biotechnology

12 January 2022

Rise of AI continues to re-write life sciences IP strategies in 2022

A spate of pharma-high tech innovation partnerships have dominated opening days of the year

11 January 2022

AbbVie heads to the ITC in dramatic final battle over Humira biosimilars

Chicago-based company seeking to exclude Alvotech’s adalimumab product from the US market for alleged trade secret misappropriation

10 January 2022

Landmark Dutch appeal court decision reduces risk of third-party damages against pharma patentees

The appellate ruling overturns a recent lower court judgment which exposed life sciences IP plaintiffs to significant additional dangers from health insurer lawsuits

06 January 2022

Get unlimited access to all IAM content